Head

Dr. Melvin George

Incharge, Department of CCTR

Dr. Melvin George leads the Centre for Clinical Trials and Research at SRM Medical College Hospital, overseeing first-in-human through phase IV programmes across therapeutic areas. His work bridges translational pharmacology and regulatory-grade trial execution.

Biography

Dr. Melvin George leads the Centre for Clinical Trials and Research at SRM Medical College Hospital, overseeing first-in-human through phase IV programmes across therapeutic areas. His work bridges translational pharmacology and regulatory-grade trial execution.

Govt funded projects as PI:

Other major projects as the investigator

Significant achievements

Recognized as Nodal Officer, ICMR Centre for Clinical Trials at SRM Medical College through ICMR

Key Responsibilities

Research Interests

Ongoing trials

Awards

Grants received

ICMR Funded Projects

Publications

  • Masilamani M, George M. Regulatory Landscape of Clinical Trials in India: Current Trends and Future Prospects. Ther Innov Regul Sci. 2026;60(1):45-58.
  • Bibi R, George M, Sarkar K. STAT4 mediated modulation of T-B cell interactions profiling in NSCLC. Mol Biol Rep. 2026;53(1):112.
  • Mukherjee O, George M, Sarkar K. STAT2 Mediated Epigenetic and Epitranscriptomic Regulation of T Helper Cell Differentiation. Immunology. 2026;170(2):210-225.
  • Mani V, George M, et al. Assessment of intrinsic capacity using step 2 assessment tools among older adults in India. Aging Clin Exp Res. 2026;38(1):88-96.
  • Mukherjee O, Bose S, George M, Sarkar K. Involvement of CCCTC-binding factor (CTCF) in immunomodulation and epigenetic regulation of T helper cell differentiation. Clin Immunol. 2026;250:109-120.
  • Bibi R, George M, Sarkar K. RNA-guided STAT3 modification fine tunes the epigenetic and epitranscriptomic landscape in NSCLC. Med Oncol. 2025;42(3):45.
  • Roy S, Shanmugam G, George M, Sarkar K. Brahmi (Bacopa monnieri) plant preparation facilitates immunotherapeutic modulation in invasive ductal carcinoma. J Cancer Res Clin Oncol. 2025;151(2):332-345.
  • Bibi R, George M, Sarkar K. Role of Trichostatin A (TSA) in modulating the epigenetic landscape of CD4+ T cells. Clin Epigenetics. 2025;17(1):12.
  • Bindu S, Mukherjee O, George M, Sarkar K. Interferon-alpha 2b (IFNα2b) enhances monocyte-derived dendritic cell maturation and immune function. Mol Biol Rep. 2025;52(4):201-210.
  • Bibi R, George M, Sarkar K. Epigenetic and Epitranscriptomic Modulation by STAT1: Unraveling T Helper Cell Differentiation in NSCLC. J Immunother. 2025;48(2):88-97.
  • Bibi R, George M, Sarkar K. Epigenetic control of T helper cells differentiation via STAT3 signaling in lung cancer. Med Oncol. 2025;42(1):15.
  • Goenka L, George M, et al. Evaluation of the current status of ethics committees in India: A cross-sectional survey. Perspect Clin Res. 2025;16(1):22-30.
  • Masilamani M, George M. The Epigenetic Landscape: From Molecular Mechanisms to Biological Aging. Rejuvenation Res. 2025;28(1):5-18.
  • Bibi R, George M, Sarkar K. Exploring the regulatory role of mtTFA in T helper cell-mediated immune responses. Int Immunopharmacol. 2025;140:112-125.
    Jinson J, George M, et al. Development of a near infrared region based non-invasive therapy device for wound healing. Sci Rep. 2024;14:15234.
  • Masilamani M, George M. Clinical trial trends over the last 5 years among the BRICS nations. Perspect Clin Res. 2024;15(3):134-140.
  • Mukherjee O, George M, Sarkar K. WASp-deficient Th1 cells exhibit altered epigenetic landscapes in inflammatory conditions. Clin Immunol. 2024;242:109-118.
  • Roy S, George M, Sarkar K. Immunomodulatory effects of Diospyros peregrina fruit preparation in experimental oncology. Med Oncol. 2024;41(5):102.
  • Bibi R, George M, Sarkar K. Association of WASp in epigenetic regulation of T helper cells. Med Oncol. 2023;40(12):356.
    Bibi R, George M, Sarkar K. Doxorubicin induced epigenetic regulation of dendritic cell maturation. Pathol Res Pract. 2024;254:155-164.
  • Venugopal P, George M, et al. Prediction of maternal and foetal outcomes among patients with preeclampsia using biomarkers. Placenta. 2023;138:45-52.
  • Bibi R, George M, Sarkar K. HDAC inhibition regulates oxidative stress in CD4+ T helper cells. Int Immunopharmacol. 2023;120:110-120.
  • Goenka L, George M. Fathoming the Role of Semaglutide in Obesity Therapeutics. Clin Ther. 2023;45(8):712-724.
  • Bibi R, George M, Sarkar K. Depletion of EZH2 directs transcription factors in T helper cell differentiation. Med Oncol. 2023;40(6):182.
  • Bhootra S, George M, Sarkar K. Diospyros malabarica fruit preparation mediates immunotherapeutic modulation in NSCLC. J Ethnopharmacol. 2023;312:116-128.
  • Goenka L, George M. Evaluation of Endpoints Used in Clinical Trials on Adenomyosis. Rev Recent Clin Trials. 2023;18(2):98-105.
  • Surendran AM, George M, Sarkar K. Immunomodulatory Role of Diospyros peregrina in Breast Cancer. Clin Breast Cancer. 2023;23(4):345-356.
  • Shanmugam G, George M, Sarkar K. Electropotential-Inspired Star-Shaped Gold Nanoconfined MWCNTs for Biosensing. ACS Appl Bio Mater. 2022;5(9):4120-4132.
  • Venugopal P, George M, et al. Prioritization of microRNA biomarkers for a prospective evaluation in myocardial infarction. Front Cardiovasc Med. 2022;9:856412.
  • Idhrees M, George M, et al. The motivators and barriers to a career in cardiothoracic surgery in India. Indian J Thorac Cardiovasc Surg. 2022;38:156-164.
  • Bibi R, George M, Sarkar K. Involvement of inflammatory cytokines and mtTFA complex in T helper cell senescence. Mol Immunol. 2022;148:12-24.
  • Mukherjee O, George M, Sarkar K. Involvement of XPG in immunomodulatory signaling in CD4+ cells. Immunobiology. 2022;227(4):152-162.
  • Bibi R, George M, Sarkar K. T helper cell-mediated epitranscriptomic regulation via m6A RNA methylation. J Cancer Res Clin Oncol. 2022;148(5):1012-1025.
  • Goenka L, George M, et al. Knowledge and attitudes on plagiarism among undergraduate medical students in India. BMC Med Educ. 2022;22:156.
  • Goenka L, George M. Efficacy of pharmacological interventions in COVID-19: A systematic review. Br J Clin Pharmacol. 2022;88(6):2534-2550.
  • Goenka L, George M. Evaluation of pharmacological interventions in the management of adenomyosis. Eur J Clin Pharmacol. 2022;78(4):512-524.
  • Bibi R, George M, Sarkar K. R-loop modulated epigenetic regulation in T helper cells during cancer. Transl Oncol. 2021;14(8):101124.
  • Howard C, George M, et al. TEVAR for complicated and uncomplicated type B aortic dissection: Systematic review. J Card Surg. 2021;36(10):3820-3830.
  • Roy S, George M, Sarkar K. Diospyros Peregrina Mediated Immunomodulation of Lymphocytes. Iran J Immunol. 2021;18(2):145-156.
  • Shanmugam S, George M, et al. Clinical outcomes among COVID-19 patients managed with modern and Siddha medicine. J Ayurveda Integr Med. 2022;13(1):100412.
  • Goenka L, George M, et al. Attitudes on plagiarism among post-graduate resident doctors in India. BMJ Open. 2021;11(6):e045612.
  • Venugopal P, George M, et al. Alirocumab in Post ACS Patients - Saving Lives at a Premium. Curr Cardiol Rev. 2022;18(1):e120521193356.
  • Srivatsan V, George M, et al. Assessment of PBMC Senescence and Endothelial Dysfunction in CAD. Arq Bras Cardiol. 2021;116(5):940-948.
  • George M, et al. Clinical Pharmacokinetic Drug Interaction Potential of MenoAct851. Curr Ther Res Clin Exp. 2020;92:100588.
  • Srivatsan V, George M, et al. Long Term Prognostic Utility of MMP-9 in Acute Coronary Syndrome. Curr Pharm Biotechnol. 2021;22(4):512-524.
  • George M, et al. Factors Influencing Levels of ST-2, Galectin-3 and MMP-9 in ACS. Cardiovasc Hematol Disord. 2020;20(2):124-132.
  • Goenka L, George M, et al. Assessment of quality of RCTs published in Indian medical journals. Perspect Clin Res. 2019;10(2):79-83.
  • Goenka L, George M. Neuroprotective agents in Acute Ischemic Stroke-A Reality Check. Biomed Pharmacother. 2019;109:2539-2547.
  • Goenka L, George M. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy. Curr Clin Pharmacol. 2019;14(2):78-83.
  • Goenka L, George M. Novel approaches in the treatment of diabetic cardiomyopathy. Biomed Pharmacother. 2018;104:412-422.
  • Jha D, George M, et al. Prognostic role of soluble ST2 in acute coronary syndrome with diabetes. Eur J Clin Invest. 2018;48(9):e12994.
  • George M, et al. Do ANGPTL-4 and galectin-3 reflect the severity of coronary artery disease? Ther Adv Cardiovasc Dis. 2017;11(1):15-24.
  • Goenka L, George M. A peek into the drug development scenario of endometriosis. Biomed Pharmacother. 2017;90:575-585.
  • George M, et al. Effect of metformin on exercise capacity in metabolic syndrome. Diabetes Metab Syndr. 2017;11:S31-S37.
  • George M, et al. End points in heart failure-are we doing it right? Eur J Clin Pharmacol. 2017;73(4):395-404.
  • Shanmugam E, George M, et al. Effect of tolvaptan on acute heart failure with hyponatremia. Indian Heart J. 2016;68:S15-S21.
  • George M, et al. Molecular analysis of the LDLR gene in coronary artery disease patients in India. Clin Biochem. 2016;49(7-8):552-560.
  • George M, et al. Evaluation of Endothelial and Platelet Derived Microparticles in ACS. J Clin Diagn Res. 2015;9(12):OC09-12.
  • George M, et al. GDF 15—A Novel Biomarker in the Offing for Heart Failure. Curr Cardiol Rev. 2016;12(1):37-46.
  • Palaniappan M, George M, et al. Pattern of Adverse Drug Reactions Reported with Cardiovascular Drugs. J Clin Diagn Res. 2015;9(11):FC01-04.
  • George M, et al. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition. J Cardiovasc Pharmacol. 2016;67(1):15-22.
  • George M, et al. Value of pentraxin-3 and galectin-3 in acute coronary syndrome. Ther Adv Cardiovasc Dis. 2015;9(5):275-284.
  • Sandhiya S, George M, et al. Comparison of ranolazine and trimetazidine in diabetic CAD patients. J Clin Diagn Res. 2015;9(1):OC01-05.
  • George M, et al. Riociguat: Something new in pulmonary hypertension therapeutics? J Pharmacol Pharmacother. 2015;6(1):3-8.
  • Srivatsan V, George M, et al. Utility of galectin-3 as a prognostic biomarker in heart failure. Eur J Prev Cardiol. 2015;22(9):1096-1110.
  • George M, et al. Looking into the crystal ball-upcoming drugs for dyslipidemia. J Cardiovasc Pharmacol Ther. 2015;20(1):12-24.
  • George M, et al. Pharmacovigilance for psychiatrists: An introduction. Indian J Psychiatry. 2014;56(2):176-181.
  • George M, et al. Novel drug targets in clinical development for heart failure. Eur J Clin Pharmacol. 2014;70(7):765-774.
  • George M, et al. New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther. 2014;19(1):65-76.
  • George M, et al. Clinical trials in India: Where do we stand globally? Perspect Clin Res. 2013;4(3):160-167.
  • Sandhiya S, Melvin G, et al. The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013;4(1):4-7.
  • George M, et al. Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013;69(8):1497-1509.